Approval · Notice of Compliance 36854 · 2026
AJOVY: Notice of Compliance 36854
Issued February 5, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36854
- Date
- February 5, 2026
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: PrAJOVY® (fremanezumab solution for subcutaneous injection) is indicated for:• the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 years and weighing at least 45 kg.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AJOVY | Not yet assigned | — |
Medicinal ingredients
- FREMANEZUMAB 225 MG per 1.5ML